Vimian Group AB (publ) (VIMGF)
USD 3.5
(-14.29%)
USD 3.5
(-14.29%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 491.12 Million USD | 4.61% |
| 2022 | 469.46 Million USD | 46.82% |
| 2021 | 319.74 Million USD | 51.05% |
| 2020 | 211.67 Million USD | 300.59% |
| 2019 | 52.84 Million USD | 238.67% |
| 2018 | 15.6 Million EUR | 0.0% |
| 2017 | - EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 340.71 Million USD | -30.69% |
| 2024 Q3 | 389.79 Million USD | 21.93% |
| 2024 Q1 | 461.24 Million EUR | 3.19% |
| 2023 Q1 | 534.7 Million USD | 13.9% |
| 2023 Q4 | 491.12 Million USD | -2.12% |
| 2023 Q3 | 501.74 Million USD | -5.87% |
| 2023 Q2 | 533.04 Million USD | -0.31% |
| 2023 FY | 491.12 Million USD | 4.61% |
| 2022 Q4 | 469.46 Million USD | 0.69% |
| 2022 FY | 469.46 Million USD | 46.82% |
| 2022 Q3 | 466.23 Million USD | -6.65% |
| 2022 Q2 | 499.42 Million EUR | 2.35% |
| 2022 Q1 | 487.94 Million EUR | 52.6% |
| 2021 Q4 | 319.75 Million EUR | 32.08% |
| 2021 FY | 319.74 Million USD | 51.05% |
| 2021 Q2 | 240.08 Million EUR | 7.77% |
| 2021 Q3 | 242.09 Million EUR | 0.84% |
| 2021 Q1 | 222.77 Million EUR | 28.55% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 211.67 Million USD | 300.59% |
| 2020 Q4 | 173.3 Million EUR | 0.0% |
| 2019 FY | 52.84 Million USD | 238.67% |
| 2018 FY | 15.6 Million EUR | 0.0% |
| 2017 FY | - EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -13512.08% |
| Arrayit Corporation | 7.49 Million USD | -6451.294% |
| Atlantic International Corp. | 3.82 Million USD | -12727.706% |
| Biocept, Inc. | 22.01 Million USD | -2131.063% |
| Bioqual, Inc. | 18.93 Million USD | -2493.326% |
| CardioGenics Holdings Inc | 1.79 Million USD | -27261.834% |
| DermTech, Inc. | 64.75 Million USD | -658.434% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 33.178% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -3865.166% |
| iMD Companies, Inc. | 1.67 Million USD | -29234.557% |
| IDenta Corp. | 1.01 Million USD | -48374.557% |
| Interpace Biosciences, Inc. | 28.15 Million USD | -1644.234% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -164735.979% |
| InVitro International | 78.99 Thousand USD | -621654.469% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -2389.35% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -379741.648% |
| Medical Imaging Corp. | 9.51 Million USD | -5060.444% |
| NovelStem International Corp. | 4.2 Million USD | -11576.525% |
| Optigenex Inc. | 9.57 Million USD | -5031.579% |
| PharmChem, Inc. | 558.64 Thousand USD | -87813.093% |
| Proteome Sciences plc | 18.48 Million USD | -2556.295% |
| Response Genetics, Inc | 15.86 Million USD | -2995.253% |
| Rennova Health, Inc. | 49.66 Million USD | -888.826% |
| RushNet, Inc. | 6.23 Million USD | -7771.846% |
| ScreenPro Security Inc. | 1.6 Million USD | -30583.984% |
| Stella Diagnostics Inc. | 18 Million USD | -2627.647% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -5886.403% |
| Todos Medical Ltd. | 50.15 Million USD | -879.173% |